Skip to content

MBX Biosciences, Inc. MBX Increase (Decrease) in Other Operating Assets

Increase (Decrease) in Other Operating Assets at other companies

Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
$2K+115%
Opko Health logo
Opko HealthOPK
$126K-87.0%
Mannkind logo
MannkindMNKD
$2.42M+45.5%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$1.36M
Amgen logo
AmgenAMGN
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.3B+475%
Enterprise value$2.26B+533%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingAssets.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s increase (decrease) in other operating assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s increase (decrease) in other operating assets?
MBX Biosciences, Inc. (MBX) reported increase (decrease) in other operating assets of $43K in Q1 2026.
What does increase (decrease) in other operating assets mean?
This captures the net change in miscellaneous assets that are not classified as loans, securities, or property, plant, and equipment. It often includes items like accrued interest receivables, prepaid expenses, and other short-term operational assets.